|
US4515810A
(en)
*
|
1983-10-06 |
1985-05-07 |
American Cyanamid Company |
Composition of matter
|
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5004651A
(en)
*
|
1989-01-24 |
1991-04-02 |
Abbott Laboratories |
Stabilizing system for solid dosage forms
|
|
AU645070B2
(en)
*
|
1990-04-10 |
1994-01-06 |
Nb International Technologies |
Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
NZ336898A
(en)
|
1997-04-28 |
2001-10-26 |
Texas Biotechnology Corp |
Sulfonamides for treatment of endothelin-mediated disorders
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
US7169410B1
(en)
*
|
1998-05-19 |
2007-01-30 |
Sdg, Inc. |
Targeted liposomal drug delivery system
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
AU1624801A
(en)
|
1999-11-19 |
2001-05-30 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists related applications
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
US6696473B2
(en)
*
|
2001-12-21 |
2004-02-24 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
|
CA2469435A1
(en)
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Modulators of lxr
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
WO2004002476A2
(en)
|
2002-06-27 |
2004-01-08 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
EP1606291A2
(en)
|
2002-07-02 |
2005-12-21 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its dervatives
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
PT1603541E
(pt)
|
2003-03-05 |
2010-02-19 |
Halozyme Inc |
Glicoproteína hialuronidase solúvel (shasegp), processo para preparação da mesma, suas utilizações e composições farmacêuticas que a compreendem.
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
US7244739B2
(en)
*
|
2003-05-14 |
2007-07-17 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
|
WO2005000298A2
(en)
*
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
5-membered heterocycle-based p-38 inhibitors
|
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
|
EP1911754B1
(en)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US20050203184A1
(en)
|
2003-09-10 |
2005-09-15 |
Petasis Nicos A. |
Benzo lipoxin analogues
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
CA2583087C
(en)
|
2003-09-19 |
2012-07-10 |
Galileo Pharmaceuticals, Inc. |
Chroman derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
US8519158B2
(en)
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
WO2005112913A1
(en)
|
2004-05-20 |
2005-12-01 |
The Scripps Research Institute |
Transthyretin stabilization
|
|
EP1765332A2
(en)
*
|
2004-06-17 |
2007-03-28 |
Cengent Therapeutics, Inc. |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
US20060135483A1
(en)
*
|
2004-07-09 |
2006-06-22 |
Cheruvallath Zacharia S |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
CA2573644A1
(en)
|
2004-07-12 |
2006-02-16 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
|
US20060034978A1
(en)
*
|
2004-08-16 |
2006-02-16 |
Grain Processing Corporation |
Aerosol compositions, devices and methods
|
|
WO2006028970A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
CA2580767A1
(en)
|
2004-09-17 |
2006-03-30 |
Whitehead Institute For Biomedical Research |
Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
|
|
US8101745B2
(en)
|
2004-12-16 |
2012-01-24 |
The Regents Of The University Of California |
Lung-targeted drugs
|
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
WO2006137953A1
(en)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
CN101309688B
(zh)
|
2005-05-23 |
2016-06-22 |
自然选择国际公司 |
持续释放β-丙氨酸的组合物和方法
|
|
WO2006138347A2
(en)
*
|
2005-06-17 |
2006-12-28 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
WO2007076160A2
(en)
*
|
2005-12-28 |
2007-07-05 |
Acidophil Llc |
C-10 carbamates of taxanes
|
|
JP2009530284A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
拡張期心不全を治療するための方法と組成物
|
|
EP2001446A2
(en)
*
|
2006-03-13 |
2008-12-17 |
Encysive Pharmaceuticals, Inc |
Formulations of sitaxsentan sodium
|
|
EP2383271B1
(en)
|
2006-03-13 |
2013-07-10 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolones as GSK-3 Inhibitors
|
|
EP2007373A4
(en)
*
|
2006-03-29 |
2012-12-19 |
Foldrx Pharmaceuticals Inc |
INHIBITION OF ALPHA SYNUCLEINE TOXICITY
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
KR101374983B1
(ko)
|
2006-08-28 |
2014-03-17 |
라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 |
길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
|
|
KR20090068263A
(ko)
|
2006-09-21 |
2009-06-25 |
액티브스 바이오사이언시즈, 인크. |
세린 가수분해효소 억제제
|
|
JP2010505961A
(ja)
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
EP2079696A2
(en)
|
2006-10-09 |
2009-07-22 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
EP2617423A1
(en)
|
2006-10-19 |
2013-07-24 |
Genzyme Corporation |
Purine derivatives for the treatment of cystic diseases
|
|
DE602007013440D1
(de)
|
2006-10-19 |
2011-05-05 |
Auspex Pharmaceuticals Inc |
Substituierte indole
|
|
EP2089359A2
(en)
|
2006-10-31 |
2009-08-19 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
KR20090086115A
(ko)
*
|
2006-12-22 |
2009-08-10 |
엔싸이시브 파마슈티칼즈 인코퍼레이티드 |
Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
CA2696053A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases
|
|
EP2514740B1
(en)
|
2007-03-15 |
2018-12-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated o-desmethylvenlafaxines with serotoninergic and/or norepinephrinergic activity
|
|
AU2008274941A1
(en)
*
|
2007-07-12 |
2009-01-15 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
|
CN102351880B
(zh)
*
|
2007-09-11 |
2014-11-12 |
杏林制药株式会社 |
作为gsk-3 抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
|
|
WO2009035684A1
(en)
|
2007-09-12 |
2009-03-19 |
Activx Biosciences, Inc. |
Spirocyclic aminoquinolones as gsk-3 inhibitors
|
|
NZ584760A
(en)
|
2007-09-25 |
2012-03-30 |
Takeda Pharmaceutical |
Polo-like kinase inhibitors
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
JP5645667B2
(ja)
|
2007-11-08 |
2014-12-24 |
アムビト ビオスシエンセス コルポラチオン |
増殖性疾患を治療するための、Ｎ−（５−ｔｅｒｔ−ブチル−イソキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，ｌ−ｂ］［ｌ，３］ベンゾチアゾール−２−イル］フェニル｝尿素の投与方法
|
|
WO2009066152A2
(en)
|
2007-11-21 |
2009-05-28 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
|
CA2709677C
(en)
|
2007-12-21 |
2017-03-14 |
Lin Zhi |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
ES2547406T3
(es)
|
2008-03-17 |
2015-10-06 |
Ambit Biosciences Corporation |
Derivados de moduladores como moduladores de quinasas RAF y metodo de uso de los mismos
|
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
RU2010151944A
(ru)
*
|
2008-05-20 |
2012-06-27 |
Серенис Терапьютикс С.А. (Fr) |
Ниацин и нспвс для комбинированной терапии
|
|
JP2011525535A
(ja)
|
2008-06-24 |
2011-09-22 |
武田薬品工業株式会社 |
ＰＩ３Ｋ／ｍＴＯＲ阻害剤
|
|
US11016104B2
(en)
|
2008-07-01 |
2021-05-25 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
|
BRPI1007378A2
(pt)
|
2009-01-06 |
2020-08-18 |
Curemark Llc |
composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
|
|
CA2747703C
(en)
|
2009-01-06 |
2021-06-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention of infections by e. coli
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
MY159327A
(en)
|
2009-02-27 |
2016-12-25 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
|
SG174419A1
(en)
|
2009-03-23 |
2011-11-28 |
Ambit Biosciences Corp |
Methods of treatment using combination therapy
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
EP2415767B1
(en)
|
2009-03-27 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
Poly (ADP-ribose) Polymerase (PARP) Inhibitors
|
|
TW201038567A
(en)
|
2009-03-27 |
2010-11-01 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
TWI510469B
(zh)
|
2009-04-22 |
2015-12-01 |
Axikin Pharmaceuticals Inc |
２，５－雙取代芳基磺醯胺ｃｃｒ３拮抗劑
|
|
AU2010239341B2
(en)
|
2009-04-22 |
2015-07-02 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide CCR3 antagonists
|
|
AR078120A1
(es)
|
2009-04-22 |
2011-10-19 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas
|
|
SMT202000092T1
(it)
|
2009-05-14 |
2020-05-08 |
Ambit Biosciences Corp |
Formulazione essiccata a spruzzo o liofilizzata di ac220
|
|
TW201105662A
(en)
|
2009-07-07 |
2011-02-16 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
NO2451435T3
(enExample)
|
2009-07-08 |
2018-03-31 |
|
|
|
JP5715625B2
(ja)
|
2009-07-30 |
2015-05-07 |
武田薬品工業株式会社 |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP2461811B1
(en)
|
2009-08-05 |
2016-04-20 |
Idenix Pharmaceuticals LLC. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
|
AU2010282399A1
(en)
*
|
2009-08-14 |
2012-03-01 |
Cerenis Therapeutics Holding S.A. |
Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
|
US8940790B2
(en)
*
|
2009-11-03 |
2015-01-27 |
Bernard Charles Sherman |
Stable pharmaceutical formulations comprising lubiprostone
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011057214A2
(en)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
WO2011075615A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
WO2011079313A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Map Pharmaceuticals, Inc. |
Novel ergoline analogs
|
|
EP2521721B1
(en)
*
|
2009-12-30 |
2014-10-01 |
Shanghai Fochon Pharmaceutical Co. Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
|
WO2011097079A1
(en)
|
2010-02-03 |
2011-08-11 |
Takeda Pharmaceutical Company Limited |
Apoptosis signal-regulating kinase 1 inhibitors
|
|
DK2542542T3
(en)
|
2010-03-02 |
2015-07-20 |
Axikin Pharmaceuticals Inc |
ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
CA2793391A1
(en)
|
2010-03-17 |
2011-09-22 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide ccr3 antagonists
|
|
US9408831B2
(en)
|
2010-04-07 |
2016-08-09 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
|
WO2011153199A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
|
CN104945318A
(zh)
|
2010-06-01 |
2015-09-30 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
|
MX367469B
(es)
|
2010-06-07 |
2019-08-23 |
Novomedix Llc |
Compuestos furanilo y su uso.
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
|
EP2611812A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
AU2011296078B2
(en)
|
2010-09-01 |
2015-06-18 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
US8633207B2
(en)
|
2010-09-01 |
2014-01-21 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
AU2011296046B2
(en)
|
2010-09-01 |
2015-05-14 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
|
US8859502B2
(en)
|
2010-09-13 |
2014-10-14 |
Celgene Corporation |
Therapy for MLL-rearranged leukemia
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
AU2011313906B2
(en)
|
2010-10-11 |
2015-08-13 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide CCR3 antagonists
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
|
AU2012236834B2
(en)
|
2011-03-28 |
2015-12-10 |
Mei Pharma, Inc |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
|
BR112013024909A2
(pt)
|
2011-03-28 |
2019-09-24 |
Mei Pharma Inc |
composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
|
|
US20140088103A1
(en)
|
2011-03-28 |
2014-03-27 |
Mei Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
EP2701733B1
(en)
|
2011-04-21 |
2019-04-03 |
Curemark, LLC |
Compounds for the treatment of neuropsychiatric disorders
|
|
WO2012177962A1
(en)
|
2011-06-23 |
2012-12-27 |
Map Pharmaceuticals, Inc. |
Novel fluoroergoline analogs
|
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
|
AU2012301616B2
(en)
|
2011-09-02 |
2018-02-08 |
Syndax Pharmaceuticals, Inc. |
Methods for the treatment of breast cancer
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
CA2849708A1
(en)
|
2011-09-23 |
2013-03-28 |
Celgene Corporation |
Romidepsin and 5 - azacitidine for use in treating lymphoma
|
|
WO2013049093A1
(en)
|
2011-09-26 |
2013-04-04 |
Celgene Corporation |
Combination therapy for chemoresistant cancers
|
|
SG11201401946QA
(en)
|
2011-11-01 |
2014-05-29 |
Celgene Corp |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
|
CA2859173A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
WO2013095708A1
(en)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
PT2822936T
(pt)
|
2012-03-07 |
2021-12-02 |
Univ Of Delhi |
Derivados da aminoquinolina e suas utilizações
|
|
US8916555B2
(en)
|
2012-03-16 |
2014-12-23 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
WO2013148919A1
(en)
|
2012-03-30 |
2013-10-03 |
The Regents Of The University Of Colorado, A Body Corporate |
Treatment of multiple myeloma
|
|
DK2844637T5
(en)
|
2012-05-02 |
2018-08-13 |
Boehringer Ingelheim Int |
SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS BY SSAO AND USES THEREOF
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP3406598B1
(en)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US8551535B1
(en)
|
2012-08-06 |
2013-10-08 |
Sarah McCann |
Homeopathic remedies and methods for enhancing weight loss
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
US9156799B2
(en)
|
2012-09-07 |
2015-10-13 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
AU2013202506B2
(en)
|
2012-09-07 |
2015-06-18 |
Celgene Corporation |
Resistance biomarkers for hdac inhibitors
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
EP2916830A2
(en)
|
2012-11-08 |
2015-09-16 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
AU2013202507B9
(en)
|
2012-11-14 |
2015-08-13 |
Celgene Corporation |
Inhibition of drug resistant cancer cells
|
|
ES2689921T3
(es)
|
2012-11-30 |
2018-11-16 |
Novomedix, Llc |
Biarilsulfonamidas sustituidas y sus usos
|
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
|
WO2014100354A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
NZ630746A
(en)
|
2013-01-11 |
2017-02-24 |
Summa Health System |
Vitamins c and k for treating polycystic diseases
|
|
AU2014218666B2
(en)
|
2013-02-22 |
2018-11-01 |
University Of Southern California |
Methods for treatment of ophthalmic diseases and disorders
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
KR102230461B1
(ko)
|
2013-03-15 |
2021-03-22 |
유니버시티 오브 써던 캘리포니아 |
엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
|
|
SI2970346T1
(sl)
|
2013-03-15 |
2018-12-31 |
The Regents Of The University Of California |
Aciklični diestri nukleozid fosfonata
|
|
US9968627B2
(en)
|
2013-03-26 |
2018-05-15 |
Celgene Corporation |
Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
|
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
US9714232B2
(en)
|
2013-12-20 |
2017-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted piperazine compounds and methods of use thereof
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
US10202398B2
(en)
|
2014-03-20 |
2019-02-12 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
|
CN114940673B
(zh)
|
2014-03-20 |
2025-03-18 |
卡佩拉医疗公司 |
苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
|
|
EP3312164B1
(en)
|
2014-03-28 |
2020-12-09 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
|
JP2017515854A
(ja)
|
2014-05-12 |
2017-06-15 |
クオナトウス ファーマシューティカルズ，インコーポレイテッド |
カスパーゼ阻害剤による慢性肝疾患の合併症の治療
|
|
WO2015195786A2
(en)
|
2014-06-17 |
2015-12-23 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
JP6543342B2
(ja)
|
2014-08-14 |
2019-07-10 |
アルハマドシャー，マモウン，エム． |
血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
|
|
PT3194411T
(pt)
|
2014-09-15 |
2022-06-06 |
Univ California |
Análogos de nucleótidos
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
EP3212633B1
(en)
|
2014-10-31 |
2019-12-04 |
The General Hospital Corporation |
Potent gamma-secretase modulators
|
|
HUE052771T2
(hu)
|
2014-12-11 |
2021-05-28 |
Pf Medicament |
C10orf54 elleni antitestek és alkalmazásuk
|
|
JP6450010B2
(ja)
|
2014-12-23 |
2019-01-09 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
３，５−ジアミノピラゾールキナーゼ阻害剤
|
|
CN107405346A
(zh)
|
2015-01-20 |
2017-11-28 |
Xoc制药股份有限公司 |
异麦角灵化合物及其用途
|
|
JP6856532B2
(ja)
|
2015-01-20 |
2021-04-07 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
エルゴリン化合物およびその使用
|
|
ES2937020T3
(es)
|
2015-03-03 |
2023-03-23 |
Kymab Ltd |
Anticuerpos, usos y métodos
|
|
BR112017020002A2
(en)
|
2015-03-20 |
2018-06-19 |
Syndax Pharmaceuticals, Inc. |
COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT
|
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
|
MY189806A
(en)
|
2015-06-23 |
2022-03-08 |
Neurocrine Biosciences Inc |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
HRP20191424T2
(hr)
|
2015-08-17 |
2021-06-25 |
Kura Oncology, Inc. |
Metode liječenja pacijenata oboljelih od raka pomoću inhibitora farnezil transferaze
|
|
KR102631377B1
(ko)
|
2015-09-02 |
2024-01-29 |
신닥스 파마슈티컬스, 인크. |
조합 요법을 위한 환자의 선별
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3875462A1
(en)
|
2015-09-15 |
2021-09-08 |
The Regents of The University of California |
Nucleotide analogs
|
|
US20180360959A1
(en)
|
2015-09-25 |
2018-12-20 |
Universität Duisburg-Essen |
Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease
|
|
MA56137B1
(fr)
|
2015-10-30 |
2024-03-29 |
Neurocrine Biosciences Inc |
Sels de dihydrochlorure de valbénazine et leurs polymorphes
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
EP3383390A4
(en)
|
2015-12-02 |
2019-11-20 |
Astraea Therapeutics, LLC |
PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS
|
|
CA3009169A1
(en)
|
2015-12-23 |
2017-06-29 |
Neurocrine Biosciences, Inc. |
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
|
BR112018013558A2
(pt)
|
2015-12-31 |
2018-12-04 |
Conatus Pharmaceuticals Inc |
método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada
|
|
CN113662941A
(zh)
|
2016-01-08 |
2021-11-19 |
细胞基因公司 |
抗增殖化合物以及其药物组合物和用途
|
|
WO2017151836A1
(en)
|
2016-03-04 |
2017-09-08 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
JP2019513151A
(ja)
|
2016-03-08 |
2019-05-23 |
ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
カンプトテシン誘導体及びその使用
|
|
WO2017156191A1
(en)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Composite nanoparticles and uses thereof
|
|
AU2017250086A1
(en)
|
2016-04-11 |
2018-09-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
ES2939373T3
(es)
|
2016-05-13 |
2023-04-21 |
Pasteur Institut |
Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
WO2018013693A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
|
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
|
WO2018035281A1
(en)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
AU2017326558B2
(en)
|
2016-09-19 |
2022-01-06 |
Mei Pharma, Inc. |
Combination therapy
|
|
HRP20210544T1
(hr)
|
2016-11-03 |
2021-08-20 |
Kura Oncology, Inc. |
Inhibitori farneziltransferaze za uporabu u liječenju raka
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
CN116987014A
(zh)
|
2016-11-09 |
2023-11-03 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
WO2018102455A1
(en)
|
2016-12-01 |
2018-06-07 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
|
TW201827051A
(zh)
|
2016-12-02 |
2018-08-01 |
美商神經性分泌生物科學公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
MY203491A
(en)
|
2017-01-27 |
2024-06-30 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
EP3576755A4
(en)
|
2017-02-02 |
2020-12-02 |
McMaster University |
BICARBONATE AS A POTENTIALIZER OF ANTIMICROBIAL AGENTS
|
|
US10513497B2
(en)
|
2017-02-17 |
2019-12-24 |
Eidos Therapeutics, Inc. |
Process for preparing AG-10, its intermediates, and salts thereof
|
|
KR102003179B1
(ko)
|
2017-02-21 |
2019-07-23 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
AU2017406159B2
(en)
|
2017-03-30 |
2020-05-21 |
XWPharma Ltd. |
Bicyclic heteroaryl derivatives and preparation and uses thereof
|
|
US12226464B2
(en)
|
2017-04-10 |
2025-02-18 |
Curemark, Llc |
Compositions for treating addiction
|
|
CN110545837B
(zh)
|
2017-04-24 |
2022-09-27 |
清华大学 |
与自体诱导物相关的通路在诱导凋亡和抗感染治疗中的应用
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
BR112019025420A2
(pt)
|
2017-06-01 |
2020-06-16 |
Xoc Pharmaceuticals, Inc. |
Compostos policíclicos e usos destes
|
|
WO2019002228A1
(en)
|
2017-06-26 |
2019-01-03 |
Institut Pasteur |
TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
|
|
KR20200051601A
(ko)
|
2017-08-07 |
2020-05-13 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암을 치료하는 방법
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP3668837B1
(en)
|
2017-08-17 |
2022-07-06 |
XWPharma Ltd. |
Preparation and uses of reactive oxygen species scavenger derivatives
|
|
EP3675866B1
(en)
|
2017-09-01 |
2023-08-02 |
East Carolina University |
Ex vivo methods for activating immune cells
|
|
CN115475229A
(zh)
|
2017-09-04 |
2022-12-16 |
凯瑞康宁生物工程（武汉）有限公司 |
活性氧清除剂的制备及用途
|
|
PL3684333T3
(pl)
|
2017-09-21 |
2025-06-23 |
Neurocrine Biosciences, Inc. |
Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane
|
|
EP3691658A4
(en)
|
2017-10-04 |
2021-06-23 |
The Regents of The University of California |
IMMUNOMODULATOR OLIGOSACCHARIDES
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
KR20250110361A
(ko)
|
2017-10-10 |
2025-07-18 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
WO2019099353A1
(en)
|
2017-11-15 |
2019-05-23 |
California State University Northridge |
Compositions and methods for the treatment and prevention of cancer
|
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
US20210052529A1
(en)
|
2018-01-10 |
2021-02-25 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
TWI823890B
(zh)
|
2018-01-10 |
2023-12-01 |
美商克拉治療有限責任公司 |
包含苯基磺醯胺之醫藥組合物及其治療應用
|
|
IL275968B2
(en)
|
2018-01-10 |
2024-07-01 |
Xwpharma Ltd |
Ketamine prodrugs, preparations containing them and their uses
|
|
WO2019155468A1
(en)
|
2018-02-08 |
2019-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
|
|
CA3094711A1
(en)
|
2018-03-23 |
2019-09-26 |
Eidos Therapeutics, Inc. |
Methods of treating ttr amyloidosis using ag10
|
|
BR112020024062A2
(pt)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences, Inc. |
métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
|
|
WO2019217484A1
(en)
|
2018-05-07 |
2019-11-14 |
Syndax Pharmaceuticals, Inc. |
Selection of patients for combination therapy
|
|
WO2019232724A1
(en)
|
2018-06-06 |
2019-12-12 |
Xw Laboratories, Inc. |
Compounds as nuclear transport modulators and uses thereof
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
WO2020006341A1
(en)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
CA3106418A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
|
WO2020019247A1
(en)
|
2018-07-26 |
2020-01-30 |
Xw Laboratories, Inc. |
Compounds as neurokinin-1 receptor antagonists and uses thereof
|
|
EP3829640A4
(en)
|
2018-08-01 |
2022-05-25 |
McMaster University |
Methods for inhibiting microbe growth
|
|
MX2021001017A
(es)
|
2018-08-15 |
2021-04-19 |
Neurocrine Biosciences Inc |
Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2).
|
|
CA3104695A1
(en)
|
2018-08-17 |
2020-02-20 |
Eidos Therapeutics, Inc. |
Formulations of ag10
|
|
CN112004802B
(zh)
|
2018-09-30 |
2021-12-28 |
凯瑞康宁生物工程（武汉）有限公司 |
作为神经元组胺受体-3拮抗剂的化合物及其用途
|
|
WO2020092720A2
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
CA3124616A1
(en)
|
2018-12-21 |
2020-06-25 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
EP3921038A1
(en)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020181165A1
(en)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Caspase inhibitors and methods of use thereof
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CA3133929A1
(en)
|
2019-04-19 |
2020-10-22 |
Lin Zhi |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
CA3138403A1
(en)
|
2019-05-20 |
2020-11-26 |
Christopher J. MACNEVIN |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
JP2022532925A
(ja)
|
2019-05-20 |
2022-07-20 |
ニルバナ サイエンシーズ インク． |
発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
|
|
SG11202113211PA
(en)
|
2019-06-03 |
2021-12-30 |
Biotheryx Inc |
Non-hygroscopic crystalline salts of a pyrazole compound, and pharmaceutical compositions and use thereof
|
|
CA3146159A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
CA3146157A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
MX2022000570A
(es)
|
2019-07-26 |
2022-03-11 |
Espervita Therapeutics Inc |
Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
WO2021055376A1
(en)
|
2019-09-16 |
2021-03-25 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
CA3128410A1
(en)
|
2019-10-11 |
2021-04-15 |
Waterstone Pharmaceuticals (Wuhan) Co., Ltd. |
Ws-635 uses thereof in medicine
|
|
CN114845709B
(zh)
|
2019-11-05 |
2024-10-01 |
德米拉公司 |
用于治疗炎性病症的mrgprx2拮抗剂
|
|
CA3159633A1
(en)
|
2019-11-05 |
2021-05-14 |
Dermira, Inc. |
Mrgprx2 antagonists and uses thereof
|
|
CA3159628A1
(en)
|
2019-11-05 |
2021-05-14 |
Dermira, Inc. |
Mrgprx2 antagonists and uses thereof
|
|
TW202136237A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
TW202136238A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2021262992A1
(en)
|
2020-06-24 |
2021-12-30 |
Neurobo Pharmaceuticals, Inc. |
Gemcabene for treatment of cytokine storms and viral-induced inflammation
|
|
EP4149471A4
(en)
|
2020-06-30 |
2024-07-10 |
Prosetta Biosciences, Inc. |
ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
|
|
US20230312551A1
(en)
|
2020-06-30 |
2023-10-05 |
Sunshine Lake Pharma Co., Ltd. |
Salt of 2-(substituted pyrimidinyl) thiazole carboxamide compound, and composition and use thereof
|
|
WO2022007769A1
(zh)
|
2020-07-07 |
2022-01-13 |
东莞市东阳光新药研发有限公司 |
吡咯烷酰胺衍生物的盐及其用途
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20240025863A1
(en)
|
2020-09-16 |
2024-01-25 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
TW202231269A
(zh)
|
2020-10-23 |
2022-08-16 |
美商拜歐斯瑞克斯公司 |
Kras蛋白降解劑、其醫藥組合物及其治療應用
|
|
TW202237580A
(zh)
|
2020-12-14 |
2022-10-01 |
美商拜歐斯瑞克斯公司 |
Pde4降解劑、醫藥組合物及治療應用
|
|
IL303118A
(en)
|
2020-12-16 |
2023-07-01 |
Impact Biomedicines Inc |
Dosing of fedratinib
|
|
EP4284377A1
(en)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Methods for the treatment of fibrotic disease
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
JP2024510196A
(ja)
|
2021-03-10 |
2024-03-06 |
ダイス・モレキュールズ・エスブイ・インコーポレイテッド |
アルファｖベータ６およびアルファｖベータ１インテグリン阻害剤およびその使用
|
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
WO2022266249A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2022266248A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2023044297A1
(en)
|
2021-09-14 |
2023-03-23 |
Impact Biomedicines, Inc. |
Fedratinib for treating myeloproliferative disorders
|
|
JP2024539134A
(ja)
|
2021-10-22 |
2024-10-28 |
プロセッタ バイオサイエンシズ， インク． |
新規な宿主標的汎呼吸器抗ウイルス小分子治療薬
|
|
IL312132A
(en)
|
2021-11-30 |
2024-06-01 |
Kura Oncology Inc |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
JP2025501308A
(ja)
|
2022-01-03 |
2025-01-17 |
ライラック セラピューティクス， インク． |
非環式チオールプロドラッグ
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
US12168673B2
(en)
|
2022-03-02 |
2024-12-17 |
Mitopower, Inc. |
Prodrugs derived from nicotinic acid and ribose
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
EP4508044A1
(en)
|
2022-04-14 |
2025-02-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
TW202413356A
(zh)
|
2022-05-10 |
2024-04-01 |
美商拜歐斯瑞克斯公司 |
Ｃｄｋ蛋白降解劑、藥物組合物及其治療應用
|
|
WO2024020127A1
(en)
|
2022-07-21 |
2024-01-25 |
Antiva Biosciences, Inc. |
Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia
|
|
KR20250099113A
(ko)
|
2022-09-09 |
2025-07-01 |
이노보 테라퓨틱스 인코포레이티드 |
CK1α 및 DUAL CK1α/GSPT1 분해 화합물
|
|
CA3268510A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions containing 3,3'-diindolmythane for treating a closed, non-bleeding head wound
|
|
WO2024092043A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
|
US20240174672A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridone Compounds
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
EP4626865A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
TW202530223A
(zh)
|
2023-09-27 |
2025-08-01 |
美商艾索司特瑞克斯公司 |
Ｍｙｓｔ抑制劑
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025201633A1
(en)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
An agent for reducing amyloid formation
|
|
WO2025231261A1
(en)
|
2024-05-01 |
2025-11-06 |
Protego Biopharma, Inc. |
Bicyclic and heterocyclic amide compounds
|